merged_ozempic-kidney-disease.txt
<other>Processing the article to answer the questions based on the provided information.</other>
<question_number>1</question_number>
<answer>N/A</answer>
<other>The article does not specify the percentage of U.S. adults with chronic kidney disease caused by Type 1 diabetes that benefit from Ozempic.</other>
<question_number>2</question_number>
<answer>N/A</answer>
<other>No information is provided in the article about a clinical trial led by Dr. Melanie Hoenig regarding Ozempic and kidney transplants.</other>
<question_number>3</question_number>
<answer>N/A</answer>
<other>The article does not mention any blood pressure medication showing synergistic effects with Ozempic in slowing kidney decline.</other>
<question_number>4</question_number>
<answer>N/A</answer>
<other>The article does not specify the minimum threshold of cardiovascular mortality reduction required by the F.D.A. for Ozempic's expanded use.</other>
<question_number>5</question_number>
<answer>N/A</answer>
<other>The article does not mention any vitamin deficiency exacerbated by Ozempic’s interaction with kidney filtration rates.</other>
<question_number>6</question_number>
<answer>N/A</answer>
<other>The article does not provide the number of years of clinical trial data submitted by Novo Nordisk to the F.D.A. for Ozempic’s long-term safety in preventing kidney failure.</other>
<question_number>7</question_number>
<answer>N/A</answer>
<other>The article does not identify any specific genetic marker predictive of severe gastrointestinal side effects from Ozempic.</other>
<question_number>8</question_number>
<answer>N/A</answer>
<other>The article does not name a competing drug that failed Phase 3 trials due to increased risk of liver toxicity.</other>
<question_number>9</question_number>
<answer>N/A</answer>
<other>The article does not provide the total number of U.S. adults currently prescribed Ozempic for off-label weight loss.</other>
<question_number>10</question_number>
<answer>Gough</answer>
<other>The surname of the Novo Nordisk official mentioned is Gough.</other>
<question_number>11</question_number>
<answer>24 percent</answer>
<other>The likelihood of experiencing a complication such as dialysis was reduced by 24 percent for diabetic patients with chronic kidney disease when treated with Ozempic compared to a placebo.</other>
<question_number>12</question_number>
<answer>Reduction in inflammation</answer>
<other>The article suggests that the reduction in inflammation throughout the body, including the kidneys, is a potential benefit of the medication beyond its blood sugar management effects.</other>
<question_number>13</question_number>
<answer>semaglutide</answer>
<other>The compound identified by the F.D.A. as being in shortage is semaglutide.</other>
<question_number>14</question_number>
<answer>diet and exercise modifications</answer>
<other>The non-pharmacological approach recommended by doctors to help manage Type 2 diabetes is diet and exercise modifications.</other>
<question_number>15</question_number>
<answer>40 percent</answer>
<other>Approximately 40 percent of people with Type 2 diabetes are expected to eventually develop chronic kidney disease.</other>
<question_number>16</question_number>
<answer>dialysis or a transplant</answer>
<other>The specific kidney-related medical intervention indicated as having a reduced chance of being needed in patients treated with the drug is dialysis or a transplant.</other>
<question_number>17</question_number>
<answer>diet and exercise modifications</answer>
<other>The lifestyle intervention suggested by physicians as an alternative to solely relying on medications is diet and exercise modifications.</other>
<question_number>18</question_number>
<answer>cardiovascular issues</answer>
<other>The treatment is shown to lessen the risk of causing fatal outcomes from cardiovascular issues.</other>
<question_number>19</question_number>
<answer>The Food and Drug Administration (F.D.A.)</answer>
<other>The federal agency responsible for approving the expanded use of the medication for patients with both Type 2 diabetes and chronic kidney disease is the Food and Drug Administration (F.D.A.).</other>